Last reviewed · How we verify

CodaVax-H1N1 influenza vaccine

Codagenix, Inc · Phase 1 active Biologic

CodaVax-H1N1 influenza vaccine is a Biologic drug developed by Codagenix, Inc. It is currently in Phase 1 development.

At a glance

Generic nameCodaVax-H1N1 influenza vaccine
SponsorCodagenix, Inc
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CodaVax-H1N1 influenza vaccine

What is CodaVax-H1N1 influenza vaccine?

CodaVax-H1N1 influenza vaccine is a Biologic drug developed by Codagenix, Inc.

Who makes CodaVax-H1N1 influenza vaccine?

CodaVax-H1N1 influenza vaccine is developed by Codagenix, Inc (see full Codagenix, Inc pipeline at /company/codagenix-inc).

What development phase is CodaVax-H1N1 influenza vaccine in?

CodaVax-H1N1 influenza vaccine is in Phase 1.

Related